GlassScriptPhysician profile
Joel G Auerbach
NPI 1083794143
$2,509.12
in general payments reported to CMS, 2019-2025
27 companies · $825 in 2025
The $825 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $157 · 2021: $247 · 2022: $206 · 2023: $382 · 2024: $443 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $517.39 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $293.24 | 2020-2025 | Vaxneuvance, Gardasil 9, Varivax |
| Pfizer INC. | $219.72 | 2019-2024 | |
| Sanofi Pasteur INC. | $186.81 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $177.47 | 2023-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $122.86 | 2020-2025 | Doc Band |
| Glaxosmithkline, LLC. | $115.04 | 2019-2025 | Bexsero, Pediarix |
| Collegium Pharmaceutical, INC. | $101.84 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $75.32 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $74.82 | 2023-2025 | |
| Abbott Laboratories | $72.98 | 2023-2025 | Id Now Instrument |
| Corium, LLC | $65.21 | 2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $58.96 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $51.93 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $51.58 | 2023-2024 | Flumist Quadrivalent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $51.08 | 2025 | Neffy |
| Noven Therapeutics, LLC | $46.80 | 2025 | Xelstrym |
| Verrica Pharmaceuticals INC. | $44.71 | 2024-2025 | Ycanth |
| Ironshore Pharmaceuticals INC. | $24.69 | 2019 | |
| Seqirus USA INC | $23.24 | 2025 | Flucelvax |
| Galderma Laboratories, L.P. | $22.52 | 2019 | |
| Hologic Sales and Service, LLC | $22.31 | 2023 | Thinprep 2000 Processor, Aptima |
| Rhythm Pharmaceuticals, INC. | $20.11 | 2023 | Imcivree |
| Tris Pharma INC | $19.94 | 2025 | Dyanavel Xr |
| Mylan Pharmaceuticals INC. | $18.03 | 2019 | |
| Phadia US INC. | $16.95 | 2021 | |
| Mission Pharmacal Company | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Auerbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.